Aridis Pharmaceuticals, Inc. (ARDS)
OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
At close: Nov 3, 2025
Aridis Pharmaceuticals Revenue
Aridis Pharmaceuticals had revenue of $417.00K in the quarter ending September 30, 2023, with 4.51% growth. This brings the company's revenue in the last twelve months to $22.36M, up 680.42% year-over-year. In the year 2022, Aridis Pharmaceuticals had annual revenue of $3.09M with 101.37% growth.
Revenue (ttm)
22.36M
Revenue Growth
+680.42%
P/S Ratio
0.00
Revenue / Employee
604.30K
Employees
37
Market Cap
10.66K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 3.09M | 1.56M | 101.37% |
| Dec 31, 2021 | 1.54M | 535.00K | 53.50% |
| Dec 31, 2020 | 1.00M | -22.00K | -2.15% |
| Dec 31, 2019 | 1.02M | -1.74M | -62.93% |
| Dec 31, 2018 | 2.76M | 1.90M | 220.58% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Aridis Pharmaceuticals News
- 11 months ago - Aridis Provides Corporate Update - GlobeNewsWire
- 1 year ago - Aridis Provides Corporate Update - GlobeNewsWire
- 2 years ago - Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 - GlobeNewsWire
- 2 years ago - Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 2 years ago - Aridis Pharmaceuticals Announces $2 Million Offering - GlobeNewsWire
- 2 years ago - Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 - GlobeNewsWire
- 2 years ago - Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation - GlobeNewsWire
- 2 years ago - Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - Accesswire